Felix Huth

1.8k total citations
60 papers, 977 citations indexed

About

Felix Huth is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Felix Huth has authored 60 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Molecular Biology and 15 papers in Pharmacology. Recurrent topics in Felix Huth's work include Drug Transport and Resistance Mechanisms (15 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Felix Huth is often cited by papers focused on Drug Transport and Resistance Mechanisms (15 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Felix Huth collaborates with scholars based in Switzerland, United States and Germany. Felix Huth's co-authors include F Pott, Kenichi Umehara, U. Möhr, Heinrich Ernst, K. H. Friedrichs, Handan He, Hilmar Schiller, Anne Gardin, Gian Camenisch and Birk Poller and has published in prestigious journals such as Environmental Health Perspectives, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Felix Huth

56 papers receiving 926 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix Huth Switzerland 17 308 288 192 163 139 60 977
Rajinder Singh United Kingdom 20 150 0.5× 301 1.0× 105 0.5× 402 2.5× 140 1.0× 35 1.4k
Huixin Yu Netherlands 17 255 0.8× 334 1.2× 166 0.9× 315 1.9× 34 0.2× 33 1.1k
J Catalin France 19 89 0.3× 321 1.1× 207 1.1× 297 1.8× 32 0.2× 61 1.0k
Daniela Keller Germany 13 140 0.5× 164 0.6× 110 0.6× 235 1.4× 144 1.0× 17 791
Wen Xia China 23 196 0.6× 477 1.7× 56 0.3× 434 2.7× 68 0.5× 88 1.2k
Christelle Cauffiez France 23 148 0.5× 239 0.8× 295 1.5× 720 4.4× 35 0.3× 60 1.5k
Angelo Burlina Italy 16 192 0.6× 220 0.8× 57 0.3× 199 1.2× 93 0.7× 89 1.1k
Yasuna Kobayashi Japan 19 90 0.3× 784 2.7× 267 1.4× 350 2.1× 30 0.2× 51 1.4k
David de Graaf United States 11 45 0.1× 240 0.8× 263 1.4× 394 2.4× 60 0.4× 15 1.0k
Bill J. Smith United States 15 78 0.3× 143 0.5× 159 0.8× 243 1.5× 50 0.4× 25 636

Countries citing papers authored by Felix Huth

Since Specialization
Citations

This map shows the geographic impact of Felix Huth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Huth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Huth more than expected).

Fields of papers citing papers by Felix Huth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Huth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Huth. The network helps show where Felix Huth may publish in the future.

Co-authorship network of co-authors of Felix Huth

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Huth. A scholar is included among the top collaborators of Felix Huth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Huth. Felix Huth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hoch, Matthias, Felix Huth, Paul W. Manley, et al.. (2024). Clinical Pharmacology of Asciminib: A Review. Clinical Pharmacokinetics. 63(11). 1513–1528. 7 indexed citations
4.
Rodríguez-Pérez, Raquel, Birk Poller, Felix Huth, et al.. (2024). Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms. Archives of Toxicology. 99(1). 377–391. 2 indexed citations
5.
Ji, Yan, Hilmar Schiller, Michelle Quinlan, et al.. (2024). Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical Pharmacokinetics. 63(2). 155–170. 2 indexed citations
6.
Glaenzel, Ulrike, et al.. (2024). Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites. Drug Metabolism and Disposition. 52(12). 1379–1387. 2 indexed citations
7.
Huth, Felix, et al.. (2024). Improving In Vitro–In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules. Drug Metabolism and Disposition. 52(5). 345–354. 2 indexed citations
8.
Rodríguez-Pérez, Raquel, Birk Poller, Felix Huth, et al.. (2024). Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Archives of Toxicology. 98(10). 3409–3424. 2 indexed citations
9.
10.
Manley, Paul W., Felix Huth, Saliha Moussaoui, & Joseph Schoepfer. (2022). A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood–brain barrier. Bioorganic & Medicinal Chemistry Letters. 59. 128577–128577. 5 indexed citations
11.
Huth, Felix, et al.. (2021). Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space. Journal of Pharmaceutical Sciences. 110(6). 2562–2569. 19 indexed citations
12.
Umehara, Kenichi, et al.. (2019). Examining P-gp efflux kinetics guided by the BDDCS – Rational selection of in vitro assay designs and mathematical models. European Journal of Pharmaceutical Sciences. 132. 132–141. 8 indexed citations
13.
14.
Gardin, Anne, et al.. (2019). Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. European Journal of Clinical Pharmacology. 75(11). 1565–1574. 10 indexed citations
15.
Aslanis, Vassilios, Kenichi Umehara, Felix Huth, et al.. (2019). Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemotherapy and Pharmacology. 84(4). 749–757. 18 indexed citations
16.
Jin, Yi, et al.. (2017). In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. European Journal of Clinical Pharmacology. 74(4). 455–464. 23 indexed citations
17.
Umehara, Kenichi, et al.. (2016). Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction. Drug Metabolism and Personalized Therapy. 31(4). 221–228. 16 indexed citations
18.
Pott, F, et al.. (1987). Carcinogenicity studies on fibres, metal compounds, and some other dusts in rats. Experimental Pathology. 32(3). 129–152. 173 indexed citations
19.
Pott, F, et al.. (1976). [Results of animal experiments concerning the carcinogenic effect of fibrous dusts and their interpretation with regard to the carcinogenesis in humans (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 162(5-6). 467–505. 22 indexed citations
20.
Sailer, R., et al.. (1973). [Powdered contrast medium for bronchography. Animal experiments using tantulum, tungsten and Hytrast (author's transl)].. PubMed. 119(6). 727–36. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajinder Singh Breakdown of academic impact, for papers by Huixin Yu Breakdown of academic impact, for papers by J Catalin Breakdown of academic impact, for papers by Daniela Keller Breakdown of academic impact, for papers by Wen Xia Breakdown of academic impact, for papers by Christelle Cauffiez Breakdown of academic impact, for papers by Angelo Burlina Breakdown of academic impact, for papers by Yasuna Kobayashi Breakdown of academic impact, for papers by David de Graaf Breakdown of academic impact, for papers by Bill J. Smith
Rankless by CCL
2026